Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Opicapone Sources in Healthy Volunteers
NCT04265027Phase 1Completed
- Sponsor
- BIAL
- Start
- Feb 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of opicapone in Parkinson's disease (PD) (2 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma OPC concentration at Day 1, Area under the plasma concentration versus time curve from dosing to last measurable concentration at Day 1 and 3 more. Started Feb 2018; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04265027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265027.